Oligonucleotide / ASO CDMOs with Clean FDA Inspection History
Oligonucleotide CDMOs make antisense oligonucleotides (ASOs), siRNAs, and related nucleic-acid drugs by solid-phase synthesis, with downstream purification and conjugation (e.g. GalNAc). The segment has grown sharply alongside approved ASO and siRNA therapeutics.
Choosing an oligonucleotide CDMO turns on synthesis scale, chemistry breadth (phosphorothioate backbones, 2'-modifications, conjugation), purity, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.
FDA inspection outcomes across these CDMOs: 8 NAI (no action), 18 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Italy (16), United States (16), Spain (10), Germany (9), Belgium (5).
Last updated 2026-10-15. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score
Showing all operator types.
| # | CDMO | Signal Score | Quality | FDA · GMP | Last FDA inspection | Capacity | Programs |
|---|---|---|---|---|---|---|---|
| 1 |
AJ
San Diego, CA · Osaka, JP
|
83.5 | 100.0 | 0 insp · 1 GMP | None on file | — | — |
| 2 |
CD
Plankstadt, DE · Caponago, IT · Boulder, CO
|
83.1 | 99.3 | 5 insp · 17 GMP | 2025-11-14 · NAI | — | — |
| 3 |
KE
Seraing, BE
|
81.6 | 99.9 | 1 insp · 4 GMP | 2024-02-26 · VAI | — | — |
| 4 |
ND
Milford, MA
|
80.3 | 100.0 | 4 insp · 0 GMP | 2026-08-12 · NAI | — | — |
| 5 |
BA
|
79.5 | 94.3 | 5 insp · 0 GMP | 2026-05-20 · VAI | — | — |
| 6 |
CRA
|
79.5 | 100.0 | 2 insp · 18 GMP | 2025-12-02 · NAI | — | — |
| 7 |
PP
|
77.4 | 98.4 | 3 insp · 0 GMP | 2025-05-15 · VAI | — | — |
| 8 |
AL
|
74.2 | 100.0 | 2 insp · 0 GMP | 2026-05-06 · NAI | — | 1 program |
| 9 |
AX
|
71.8 | 96.8 | 4 insp · 0 GMP | 2025-01-16 · VAI | — | 3 programs |